Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...

Benzinga · Dec 4 20:02

Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And Sustained Virologic Response At 12 Weeks Post-treatment

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...

Risk Disclaimer